摘要
目的探索奥沙利铂过敏的发生率和临床特征。方法收集2008年3月至2012年12月期间曾接受至少1次奥沙利铂治疗的194例患者的临床资料,分析奥沙利铂过敏的临床特征。结果194例患者中,21例(10.8%)发生过敏反应,其中3~4度过敏发生率为4.6%。过敏最常发生于第7—8个周期,发生率为7.3%。延迟性发热是最常见的过敏症状;以呼吸和循环系统症状为主要过敏表现者,症状发生最快、程度最严重。结论中国患者奥沙利铂过敏发生率与两方人群或其他亚洲人群类似。第7~8个周期过敏发生率最高,严重过敏多发生在输注开始前10min,提醒临床医生在此期间密切关注。
Objective To explore the incidence and clinical characteristics of oxaliplatin (L- OHP) -induced hypersensitivity reactions (HRs) in Chinese patients. Methods Clinical information of all patients treated with L-OHP at least once between March 2008 and December 2012 was collected. Detail da- ta from patients who experienced HRs were analyzed. Results Among 194 patients receiving L-OHP-based chemotherapy ,21 ( 10. 8% ) experienced HRs. Grade 3/4 events occurred in 4. 6%. HRs occurred most fre- quently in cycle 7-sth ( incidence 7.3% ). The most common symptom of HRs was delayed pyrexia. The fas- test and severest HRs were observed in those manifesting mainly with respiratory or cardiac symp- toms. Conclusions The reaearch data shows the incidence of HRs to L-OHP in Chinese patients is similar to that in western population and other eastern Asian populations. Precautions are recommended for firstl0 minutes since onset of infusion and cycle 7-Sth, given the most serious events and the peak of incidence ob- served during this period.
出处
《中国肿瘤临床与康复》
2014年第2期194-197,共4页
Chinese Journal of Clinical Oncology and Rehabilitation
关键词
奥沙利铂
过敏反应
发热
Oxaliplatin
Hypersensitivity reaction
Incidence
Fever